Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Comparison of the novel CompEx asthma exacerbation endpoint to the ATS/ERS adapted moderate/severe asthma exacerbation definition used in the MITRA trial.

Eriksson G, Nolte H, Ljørring C, Riis B, Virchow JC.

Respir Med. 2019 Jul;153:1-2. doi: 10.1016/j.rmed.2019.04.014. Epub 2019 May 1. No abstract available.

PMID:
31136926
2.

Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

Miller PD, Hattersley G, Lau E, Fitzpatrick LA, Harris AG, Williams GC, Hu MY, Riis BJ, Russo L, Christiansen C.

Bone. 2019 Mar;120:137-140. doi: 10.1016/j.bone.2018.10.015. Epub 2018 Oct 22.

3.

Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children.

Masuyama K, Okamoto Y, Okamiya K, Azuma R, Fujinami T, Riis B, Ohashi-Doi K, Natsui K, Imai T, Okubo K.

Allergy. 2018 Dec;73(12):2352-2363. doi: 10.1111/all.13544. Epub 2018 Oct 10.

PMID:
30043449
4.

Identification of pain categories associated with change in pain in patients receiving placebo: data from two phase 3 randomized clinical trials in symptomatic knee osteoarthritis.

Bihlet AR, Byrjalsen I, Bay-Jensen AC, Andersen JR, Christiansen C, Riis BJ, Valter I, Karsdal MA, Hochberg MC.

BMC Musculoskelet Disord. 2018 Jan 17;19(1):17. doi: 10.1186/s12891-018-1938-5.

5.

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.

Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D.

Mayo Clin Proc. 2017 Feb;92(2):200-210. doi: 10.1016/j.mayocp.2016.10.009.

6.

Cohort Profile: The Prospective Epidemiological Risk Factor (PERF) study.

Neergaard JS, Dragsbæk K, Kehlet SN, Hansen HB, Hansen G, Byrjalsen I, Alexandersen P, Lindgren LM, Bihlet AR, Riis BJ, Andersen JR, Qvist P, Karsdal MA, Christiansen C.

Int J Epidemiol. 2017 Aug 1;46(4):1104-1104i. doi: 10.1093/ije/dyw251. No abstract available.

PMID:
27789666
7.

Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes.

Karsdal MA, Henriksen K, Genovese F, Leeming DJ, Nielsen MJ, Riis BJ, Christiansen C, Byrjalsen I, Schuppan D.

Diabetologia. 2017 Jan;60(1):50-59. Epub 2016 Sep 8.

PMID:
27631136
8.

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators.

JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136. Erratum in: JAMA. 2017 Jan 24;317(4):442.

PMID:
27533157
9.

A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.

Henriksen K, Byrjalsen I, Andersen JR, Bihlet AR, Russo LA, Alexandersen P, Valter I, Qvist P, Lau E, Riis BJ, Christiansen C, Karsdal MA; SMC021 investigators.

Bone. 2016 Oct;91:122-9. doi: 10.1016/j.bone.2016.07.019. Epub 2016 Jul 25.

PMID:
27462009
10.

Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.

Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, Ljørring C, Riis B, de Blay F.

JAMA. 2016 Apr 26;315(16):1715-25. doi: 10.1001/jama.2016.3964.

PMID:
27115376
11.

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.

Karsdal MA, Byrjalsen I, Alexandersen P, Bihlet A, Andersen JR, Riis BJ, Bay-Jensen AC, Christiansen C; CSMC021C2301/2 investigators.

Osteoarthritis Cartilage. 2015 Apr;23(4):532-43. doi: 10.1016/j.joca.2014.12.019. Epub 2015 Jan 9.

12.

OA phenotypes, rather than disease stage, drive structural progression--identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA.

Karsdal MA, Bihlet A, Byrjalsen I, Alexandersen P, Ladel C, Michaels M, Andersen JR, Riis BJ, Kraus V, Bay-Jensen AC, Christiansen C.

Osteoarthritis Cartilage. 2015 Apr;23(4):550-8. doi: 10.1016/j.joca.2014.12.024. Epub 2015 Jan 8.

13.

Lessons learned from the clinical development of oral peptides.

Karsdal MA, Riis BJ, Mehta N, Stern W, Arbit E, Christiansen C, Henriksen K.

Br J Clin Pharmacol. 2015 May;79(5):720-32. doi: 10.1111/bcp.12557. Review.

14.

Impact of source data verification on data quality in clinical trials: an empirical post hoc analysis of three phase 3 randomized clinical trials.

Andersen JR, Byrjalsen I, Bihlet A, Kalakou F, Hoeck HC, Hansen G, Hansen HB, Karsdal MA, Riis BJ.

Br J Clin Pharmacol. 2015 Apr;79(4):660-8. doi: 10.1111/bcp.12531.

15.

SQ HDM SLIT-tablet (ALK) in treatment of asthma--post hoc results from a randomised trial.

de Blay F, Kuna P, Prieto L, Ginko T, Seitzberg D, Riis B, Canonica GW.

Respir Med. 2014 Oct;108(10):1430-7. doi: 10.1016/j.rmed.2014.07.017. Epub 2014 Aug 7.

16.

Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.

Henriksen K, Andersen JR, Riis BJ, Mehta N, Tavakkol R, Alexandersen P, Byrjalsen I, Valter I, Nedergaard BS, Teglbjaerg CS, Stern W, Sturmer A, Mitta S, Nino AJ, Fitzpatrick LA, Christiansen C, Karsdal MA.

Bone. 2013 Mar;53(1):160-6. doi: 10.1016/j.bone.2012.11.045. Epub 2012 Dec 9.

PMID:
23234813
17.

SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.

Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R.

J Allergy Clin Immunol. 2012 Mar;129(3):717-725.e5. doi: 10.1016/j.jaci.2011.12.973. Epub 2012 Jan 29.

18.

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.

Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanauskaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P.

Osteoporos Int. 2012 Jun;23(6):1747-56. doi: 10.1007/s00198-011-1773-0. Epub 2011 Sep 28.

PMID:
21953471
19.

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.

Henriksen K, Byrjalsen I, Qvist P, Beck-Nielsen H, Hansen G, Riis BJ, Perrild H, Svendsen OL, Gram J, Karsdal MA, Christiansen C; BALLET Trial Investigators.

Diabetes Metab Res Rev. 2011 May;27(4):392-401. doi: 10.1002/dmrr.1187.

PMID:
21328517
20.

Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)--assessment of corresponding epitopes.

Leeming DJ, Larsen DV, Zhang C, Hi Y, Veidal SS, Nielsen RH, Henriksen K, Zheng Q, Barkholt V, Riis BJ, Byrjalsen I, Qvist P, Karsdal MA.

Clin Biochem. 2010 Oct;43(15):1249-56. doi: 10.1016/j.clinbiochem.2010.07.025. Epub 2010 Aug 13.

PMID:
20709044
21.

Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.

Karsdal MA, Henriksen K, Bay-Jensen AC, Molloy B, Arnold M, John MR, Byrjalsen I, Azria M, Riis BJ, Qvist P, Christiansen C.

J Clin Pharmacol. 2011 Apr;51(4):460-71. doi: 10.1177/0091270010372625. Epub 2010 Jul 21. Review.

PMID:
20660294
22.
23.

Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.

Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R.

J Allergy Clin Immunol. 2010 Jan;125(1):131-8.e1-7. doi: 10.1016/j.jaci.2009.10.035.

PMID:
20109743
24.

Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy.

Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Christiansen C.

Eur J Clin Pharmacol. 2010 Jan;66(1):29-37. doi: 10.1007/s00228-009-0735-3. Epub 2009 Oct 8.

PMID:
19813008
25.

The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study.

Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Lau EM, Arnold M, Christiansen C.

Osteoarthritis Cartilage. 2010 Feb;18(2):150-9. doi: 10.1016/j.joca.2009.08.004. Epub 2009 Sep 1.

26.

Influence of food intake on the bioavailability and efficacy of oral calcitonin.

Karsdal MA, Byrjalsen I, Azria M, Arnold M, Choi L, Riis BJ, Christiansen C.

Br J Clin Pharmacol. 2009 Apr;67(4):413-20. doi: 10.1111/j.1365-2125.2009.03371.x.

27.

A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin.

Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Christiansen C.

J Clin Pharmacol. 2009 Feb;49(2):229-34. doi: 10.1177/0091270008329552.

PMID:
19179298
28.

Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin.

Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C.

BMC Clin Pharmacol. 2008 Dec 4;8:12. doi: 10.1186/1472-6904-8-12.

30.

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years.

Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, Riis B, Grønager PM, Durham SR.

J Allergy Clin Immunol. 2008 Feb;121(2):512-518.e2. Epub 2007 Dec 26.

31.
32.

Development and validation of an electronic version of the Rhinoconjunctivitis Quality of Life Questionnaire.

Juniper EF, Riis B, Juniper BA.

Allergy. 2007 Sep;62(9):1091-3. Epub 2007 May 22.

PMID:
17521314
33.

Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA?

Karsdal MA, Tanko LB, Riis BJ, Sondergard BC, Henriksen K, Altman RD, Qvist P, Christiansen C.

Osteoarthritis Cartilage. 2006 Jul;14(7):617-24. Epub 2006 May 12. Review.

34.
35.

Different effects of CSA and CSB deficiency on sensitivity to oxidative DNA damage.

de Waard H, de Wit J, Andressoo JO, van Oostrom CT, Riis B, Weimann A, Poulsen HE, van Steeg H, Hoeijmakers JH, van der Horst GT.

Mol Cell Biol. 2004 Sep;24(18):7941-8.

36.

Oligonucleotides in human urine do not contain 8-oxo-7,8-dihydrodeoxyguanosine.

Weimann A, Riis B, Poulsen HE.

Free Radic Biol Med. 2004 Jun 1;36(11):1378-82.

PMID:
15135173
37.

Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal.

Warming L, Christoffersen C, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C.

Maturitas. 2003 Mar 28;44(3):189-99.

PMID:
12648882
38.
39.

Increased rOGG1 expression in regenerating rat liver tissue without a corresponding increase in incision activity.

Riis B, Risom L, Loft S, Poulsen HE.

DNA Repair (Amst). 2002 May 30;1(5):419-24.

PMID:
12509237
40.

Dietary-induced changes of muscle growth rate in pigs: effects on in vivo and postmortem muscle proteolysis and meat quality.

Kristensen L, Therkildsen M, Riis B, Sørensen MT, Oksbjerg N, Purslow PP, Ertbjerg P.

J Anim Sci. 2002 Nov;80(11):2862-71.

PMID:
12462253
41.

Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs. A review.

Riis BJ, Lehmann HJ, Christiansen C.

Am J Obstet Gynecol. 2002 Oct;187(4):1101-16. Review.

PMID:
12389012
42.

Eukaryotic elongation factor-2 (eEF-2) activity in bovine mammary tissue in relation to milk protein synthesis.

Christophersen CT, Karlsen J, Nielsen MO, Riis B.

J Dairy Res. 2002 May;69(2):205-12.

PMID:
12222799
44.

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis.

Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C.

J Bone Miner Res. 2001 Oct;16(10):1871-8.

45.

The effect of fluvastatin on parameters of bone remodeling.

Bjarnason NH, Riis BJ, Christiansen C.

Osteoporos Int. 2001;12(5):380-4.

PMID:
11444086
46.

Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy.

Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C.

J Clin Endocrinol Metab. 2001 Feb;86(2):755-60.

PMID:
11158042
48.

Hormone replacement therapy--with or without added progestin--and which progestin?

Christiansen C, Riis BJ.

Epidemiology. 1999 Sep;10(5):471-3. No abstract available.

PMID:
10468416
49.

Clinical use of a simulation-multileaf collimator.

Marx M, Vacha P, Riis B, Feyerabend T, Richter E.

Strahlenther Onkol. 1998 Jul;174(7):355-7.

PMID:
9689956
50.

Supplemental Content

Support Center